Not Yet Recruiting PHASE2 INTERVENTIONAL 3-arm NCT07224477

A Clinical Study of V540A in Healthy Female Participants (V540A-005)

A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age

Sponsor: Merck Sharp & Dohme LLC

Conditions Healthy

Interventions GARDASIL®9 V540A-2 V540A-3

Updated 3 times since 2025 Last updated: Feb 17, 2026 Started: Jul 20, 2026 Primary completion: Apr 4, 2028 Completion: Apr 4, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Healthy and is currently actively recruiting participants. Merck Sharp & Dohme LLC leads this study, which shows 3 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Feb 2026 — Present [monthly]

Not Yet Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Not Yet Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.